Nucleoside derivatives for the treatment of cancer
WO2015134780A1
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015134561A1
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015095305A1
Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
WO2015095419A1
4'-or nucleosides for the treatment of hcv
IL235730D0
D-amino acid compounds for liver disease
WO2015066370A1
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
WO2015061683A1
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3046924A1
Hepatitis c virus inhibitors
WO2014165542A1
2',4'-fluoro nucleosides for the treatment of hcv
WO2014160484A1
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014137926A1
3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1
Thiophosphate nucleosides for the treatment of hcv
US2014178338A1
4′-fluoro nucleosides for the treatment of HCV
WO2014078427A1
D-alanine ester of rp-nucleoside analog
WO2014078436A1
D-alanine ester of sp-nucleoside analog
EP2909222A1
2',4'-bridged nucleosides for hcv infection
WO2014036244A1
Methods of administering a 5,5-fused heteroarylene hepatitis c virus inhibitor for treating of preventing hepatitis c virus infection
AU2013203974A1
Methods and compositions for treating hepatitis C virus
AU2013203341A1
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
